Biotech Values

[DewDiligence]

FWIW: I closed out my IMDC short at a $2.50 gain and used the buying power to purchase more GENR. I think today’s PR is quite positive about the future of the AMD program.

I remain somewhat concerned about MEDI’s commitment to IL-9 (today’s GENR PR was minimalist on the subject), but I am confident that internal MEDI-related issues will eventually be resolved and that the IL-9 program is attractive enough that GENR could find a new partner if necessary.

P.S. I am still short DNA and haven’t covered any of it yet.